APOLLOMICS INC (APLM) Stock Price, Forecast & Analysis
USA - NASDAQ:APLM - KYG0411D1236 - Common Stock
APLM Key Statistics, Chart & Performance
The current stock price of APLM is 12.16 USD. In the past month the price increased by 93.94%. In the past year, price decreased by -13.14%.
APLM Latest News, Press Relases and Analysis
APLM Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.94 | 382.94B | ||
| AMGN | AMGEN INC | 14.63 | 172.20B | ||
| GILD | GILEAD SCIENCES INC | 14.97 | 152.10B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.02 | 106.91B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.31 | 68.28B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 852.08 | 56.96B | ||
| ARGX | ARGENX SE - ADR | 62.07 | 51.25B | ||
| INSM | INSMED INC | N/A | 39.50B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.19 | 35.30B | ||
| NTRA | NATERA INC | N/A | 27.44B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.86B | ||
| BIIB | BIOGEN INC | 9.17 | 22.49B |
Related stock screener links
About APLM
Company Profile
Apollomics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of oncology therapies to address unmet medical needs. The company is headquartered in Foster City, California and currently employs 13 full-time employees. The company went IPO on 2021-11-26. The product candidates in its pipeline are categorized into two groups based on their mechanisms of action, each of which contains product candidates at different stages of development: tumor inhibitors and immuno-oncology drugs. Its tumor inhibitor product candidates consist of three small-molecule inhibitors against different uncontrolled growth signaling pathways in cancer cells: vebreltinib, APL-102 and APL-122. Its three immuno-oncology product candidates consist of APL-501, APL-502 and APL-80. Vebreltinib is a potent, oral active selective c-Met inhibitor. APL-102 is an oral active, small molecule Multiple Tyrosine Kinase Inhibitor. APL-122 is a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathways. APL-501 is an anti-PD-1 antibody product candidate.
Company Info
APOLLOMICS INC
989 East Hillsdale Blvd, Ste 220
Foster City CALIFORNIA US
Employees: 13
Phone: 16502094055
APOLLOMICS INC / APLM FAQ
What does APOLLOMICS INC do?
Apollomics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of oncology therapies to address unmet medical needs. The company is headquartered in Foster City, California and currently employs 13 full-time employees. The company went IPO on 2021-11-26. The product candidates in its pipeline are categorized into two groups based on their mechanisms of action, each of which contains product candidates at different stages of development: tumor inhibitors and immuno-oncology drugs. Its tumor inhibitor product candidates consist of three small-molecule inhibitors against different uncontrolled growth signaling pathways in cancer cells: vebreltinib, APL-102 and APL-122. Its three immuno-oncology product candidates consist of APL-501, APL-502 and APL-80. Vebreltinib is a potent, oral active selective c-Met inhibitor. APL-102 is an oral active, small molecule Multiple Tyrosine Kinase Inhibitor. APL-122 is a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathways. APL-501 is an anti-PD-1 antibody product candidate.
Can you provide the latest stock price for APOLLOMICS INC?
The current stock price of APLM is 12.16 USD. The price decreased by -12.2% in the last trading session.
What is the dividend status of APOLLOMICS INC?
APLM does not pay a dividend.
What is the ChartMill rating of APOLLOMICS INC stock?
APLM has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Can you provide the sector and industry classification for APOLLOMICS INC?
APOLLOMICS INC (APLM) operates in the Health Care sector and the Biotechnology industry.
APLM Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to APLM. When comparing the yearly performance of all stocks, APLM is one of the better performing stocks in the market, outperforming 93.36% of all stocks.
APLM Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to APLM. APLM may be in some trouble as it scores bad on both profitability and health.
APLM Financial Highlights
Over the last trailing twelve months APLM reported a non-GAAP Earnings per Share(EPS) of -1.93. The EPS decreased by -3757.18% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -311.63% | ||
| ROE | -418.59% | ||
| Debt/Equity | 0.01 |
APLM Forecast & Estimates
For the next year, analysts expect an EPS growth of 99.53% and a revenue growth -100% for APLM